- Home
- IHT vs KZIA Comparison
IHT vs KZIA Comparison
Compare IHT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHT
- KZIA
- Stock Information
- Founded
- IHT 1971
- KZIA 1994
- Country
- IHT United States
- KZIA Australia
- Employees
- IHT N/A
- KZIA N/A
- Industry
- IHT Investment Bankers/Brokers/Service
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- IHT Finance
- KZIA Health Care
- Exchange
- IHT Nasdaq
- KZIA Nasdaq
- Market Cap
- IHT 18.0M
- KZIA 18.7M
- IPO Year
- IHT N/A
- KZIA 1999
- Fundamental
- Price
- IHT $2.28
- KZIA $3.02
- Analyst Decision
- IHT
- KZIA Strong Buy
- Analyst Count
- IHT 0
- KZIA 1
- Target Price
- IHT N/A
- KZIA $20.00
- AVG Volume (30 Days)
- IHT 2.5K
- KZIA 85.9K
- Earning Date
- IHT 12-31-2024
- KZIA 01-03-2025
- Dividend Yield
- IHT 0.88%
- KZIA N/A
- EPS Growth
- IHT N/A
- KZIA N/A
- EPS
- IHT N/A
- KZIA N/A
- Revenue
- IHT $7,692,305.00
- KZIA $1,655,324.00
- Revenue This Year
- IHT N/A
- KZIA $806.89
- Revenue Next Year
- IHT N/A
- KZIA N/A
- P/E Ratio
- IHT N/A
- KZIA N/A
- Revenue Growth
- IHT 4.55
- KZIA 248000.00
- 52 Week Low
- IHT $1.22
- KZIA $1.90
- 52 Week High
- IHT $2.36
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- IHT 59.17
- KZIA 30.94
- Support Level
- IHT $2.06
- KZIA $2.78
- Resistance Level
- IHT $2.24
- KZIA $4.20
- Average True Range (ATR)
- IHT 0.13
- KZIA 0.55
- MACD
- IHT -0.00
- KZIA -0.13
- Stochastic Oscillator
- IHT 100.00
- KZIA 9.92
About IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.